{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-120350","form_type":"8-K","ticker":null,"cik":"0001697532","company_name":"Applied Therapeutics, Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.742991+00:00","generated_at":"2026-06-21T15:56:16.870151+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Applied Therapeutics gets Nasdaq deficiency notice as equity falls below $10M minimum","bullets":["Stockholders' equity was $9.6M as of Sep 30, 2022, below Nasdaq's $10M continued listing requirement.","Company has until Dec 30, 2022 to submit a compliance plan to regain compliance.","If plan accepted, Nasdaq may grant until May 14, 2023 to evidence compliance.","No decisions on response have been made; continued listing not assured."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-120350","json":"https://secwatch.observer/filing/0001104659-22-120350.json","markdown":"https://secwatch.observer/filing/0001104659-22-120350.md","text":"https://secwatch.observer/filing/0001104659-22-120350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697532/000110465922120350/0001104659-22-120350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697532/000110465922120350/tm2230973d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:56:16.870151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d70322813e8a69a00c80d6c3150a99e9cc7fe8a8","claim":"Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"November 15, 2022, Applied Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”) does not satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million (the “Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000110465922120350/0001104659-22-120350-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5450(b)(1)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}